Managing patients with EGFR exon 20 ins in NSCLC and EGFR TKI toxicity

Dr Danny Nguyen speaks to ecancer about managing patients with EGFR exon 20 ins in NSCLC and EGFR TKI toxicity.
Initially, he discusses the data on managing EGFR TKI toxicity from ESMO and WCLC 2021.
He then talks about the efficacy and toxicity profiles of mobocertinib, DZD9008, and amivantamab.
Dr Nguyen discusses the comparative clinical outcomes between EGFR Exon20ins and wildtype NSCLC treated with immune checkpoint inhibitors.
He also mentions other emerging data from recent conferences regarding the treatment of EGFR exon 20 ins mutation NSCLC patients.
He concludes by talking about what the future looks like for the treatment of EGFR exon 20 ins NSCLC.
Sign up to ecancer for free to receive tailored email alerts for more videos like this.
ecancer.org/account/register.php